Treatment of murine Candida krusei or Candida glabrata infection with L-743,872.

AUTOR(ES)

Graybill, J R

RESUMO

L-743,872 is a broad-spectrum pneumocandin antifungal drug developed by Merck Research Co., and in the present work it was evaluated in vivo in murine models of Candida krusei and Candida glabrata infection. Mice were infected intravenously with two isolates of C. krusei and treated with fluconazole or L-743,872. Fluconazole was beneficial only in immune-competent mice infected with isolate 94-2696. At > 0.5 mg/kg of body weight/day, L-743,872 was effective against both infecting isolates in immune-competent and immune-suppressed mice. Against C. glabrata, L-743,872 was effective, at doses > or = 0.5 mg/kg, in reducing fungal cell counts in the kidneys but not in the spleen. L-743,872 has significant potential for clinical development.

Documentos Relacionados

• Treatment of murine disseminated candidiasis with L-743,872.
• Treatment of Histoplasmosis with MK-991 (L-743,872)
• Efficacy of MK-991 (L-743,872), a Semisynthetic Pneumocandin, in Murine Models of Pneumocystis carinii
• In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).
• In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species.